ATE354584T1 - Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen - Google Patents

Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Info

Publication number
ATE354584T1
ATE354584T1 AT04029270T AT04029270T ATE354584T1 AT E354584 T1 ATE354584 T1 AT E354584T1 AT 04029270 T AT04029270 T AT 04029270T AT 04029270 T AT04029270 T AT 04029270T AT E354584 T1 ATE354584 T1 AT E354584T1
Authority
AT
Austria
Prior art keywords
solid phase
unprotected
aqueous solutions
chemical ligation
native chemical
Prior art date
Application number
AT04029270T
Other languages
English (en)
Inventor
Lynne Canne
Stephen B H Kent
Reyna Simon
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Application granted granted Critical
Publication of ATE354584T1 publication Critical patent/ATE354584T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT04029270T 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen ATE354584T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13

Publications (1)

Publication Number Publication Date
ATE354584T1 true ATE354584T1 (de) 2007-03-15

Family

ID=21960431

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98929035T ATE285415T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
AT04029270T ATE354584T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98929035T ATE285415T1 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Country Status (9)

Country Link
US (4) US6326468B1 (de)
EP (1) EP1001968B1 (de)
JP (1) JP2002505672A (de)
AT (2) ATE285415T1 (de)
AU (1) AU745094B2 (de)
CA (1) CA2292724A1 (de)
DE (2) DE69828287T2 (de)
ES (2) ES2235336T3 (de)
WO (1) WO1998056807A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
WO1998056807A1 (en) * 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
WO1999011655A1 (en) * 1997-09-04 1999-03-11 Gryphon Sciences Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
AU768118B2 (en) * 1999-03-11 2003-12-04 Gryphon Sciences Chemical synthesis and use of soluble membrane protein receptor domains
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20020155455A1 (en) * 2000-08-11 2002-10-24 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
CN1451013A (zh) * 2000-09-01 2003-10-22 格莱风治疗公司 对亲核试剂稳定的硫酯生成化合物,及其生产和使用方法
DK1353941T3 (da) * 2001-01-22 2013-06-17 Sangamo Biosciences Inc Modificerede zinkfingerbindingsproteiner
DE60216468T2 (de) * 2001-03-09 2007-09-27 Boston Probes, Inc., Bedford Kombinationsoligomere betreffende verfahren, kits und zusammensetzungen
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
EP2305312B1 (de) 2001-10-10 2015-03-04 ratiopharm GmbH Neumodulierung und Glykokonjugation von Follitropin (FSH)
WO2003106615A2 (en) * 2002-06-10 2003-12-24 Geneprot, Inc. Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation
US7208594B2 (en) * 2002-06-29 2007-04-24 Aquanova Ag Isoflavone concentrates as well as methods for their production
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
EP1578962A4 (de) * 2002-12-11 2007-03-14 New England Biolabs Inc Träger-ligand-fusionen und verwendungen davon
US8034900B2 (en) * 2002-12-30 2011-10-11 Amylin Pharmaceuticals, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
EP1615945B1 (de) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
PT1624891E (pt) * 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1631597A4 (de) * 2003-05-22 2007-07-11 Gryphon Therapeutics Inc Chemische festphasenligation mit austauschbarem linker
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
EP1725576B1 (de) * 2004-02-20 2010-09-22 Biosurface Engineering Technologies, Inc. Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2)
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
EP1749022A2 (de) * 2004-05-24 2007-02-07 Rigel Pharmaceuticals, Inc. Verfahren zur cyclisierung von synthetischen polymeren
WO2006105527A2 (en) 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US7674881B2 (en) * 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
WO2007046456A1 (ja) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha 新規水溶性プロドラッグを含有する、膵臓癌、卵巣癌または肝臓癌の予防または治療剤
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
EP2046350A4 (de) 2006-06-22 2011-09-14 Biosurface Eng Tech Inc Zusammensetzungen und verfahren zur freisetzung eines bmp-2-amplifikators/coaktivators für verstärkte osteogenese
ES2389747T3 (es) 2007-02-05 2012-10-31 Amylin Pharmaceuticals, Inc. Péptidos FN-38 para su uso en el tratamiento de desórdenes psicóticos y de ansiedad
JP2010537984A (ja) * 2007-08-28 2010-12-09 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ポリペプチドおよび蛋白質の化学合成のための方法および中間体
US8927485B2 (en) * 2010-02-18 2015-01-06 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
CN104271588B (zh) 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
WO2013170272A2 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
WO2017151939A1 (en) * 2016-03-02 2017-09-08 The Brigham And Women's Hospital, Inc. Use of pla2g5-deficient suppressive macrophages in suppression of inflammation
WO2018159721A1 (ja) * 2017-03-02 2018-09-07 株式会社糖鎖工学研究所 アミノ酸ポリマーの製造方法
CA3114571A1 (en) 2018-10-01 2020-04-09 Universite De Geneve Methods for producing a plurality of polypeptide variants suitable for biological analysis
JP7281826B2 (ja) * 2018-11-30 2023-05-26 株式会社糖鎖工学研究所 ペプチドチオエステル、ペプチドの新規製造方法
GB2604481A (en) 2019-10-10 2022-09-07 1859 Inc Methods and systems for microfluidic screening
CN110945009B (zh) * 2019-10-23 2023-10-31 烟台迈百瑞国际生物医药股份有限公司 一种寡肽连接子中间体及其制备方法
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
EP4646232A1 (de) 2023-01-06 2025-11-12 Université de Genève Variante ligandkonjugate zur nutzlastabgabe

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
AU711451B2 (en) * 1995-05-04 1999-10-14 Scripps Research Institute, The Synthesis of proteins by native chemical ligation
CA2273071C (en) * 1996-12-24 2008-07-29 The Scripps Research Institute Method for ligating oligopeptides
WO1998056807A1 (en) * 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
US20020132975A1 (en) 2002-09-19
EP1001968B1 (de) 2004-12-22
DE69837170T2 (de) 2007-11-22
US20050209440A1 (en) 2005-09-22
WO1998056807A1 (en) 1998-12-17
CA2292724A1 (en) 1998-12-17
ATE285415T1 (de) 2005-01-15
ES2282788T3 (es) 2007-10-16
US7030217B2 (en) 2006-04-18
EP1001968A1 (de) 2000-05-24
US6326468B1 (en) 2001-12-04
AU745094B2 (en) 2002-03-14
DE69828287T2 (de) 2005-12-15
DE69837170D1 (de) 2007-04-05
DE69828287D1 (de) 2005-01-27
US7094871B2 (en) 2006-08-22
ES2235336T3 (es) 2005-07-01
AU8069598A (en) 1998-12-30
JP2002505672A (ja) 2002-02-19
US20020169282A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DE69828287D1 (de) Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
NO993341L (no) Analoger av paratyroidhormon
NZ527053A (en) Modified amyloid precursor protein polynucleotides and polypeptides
GB9822692D0 (en) Chemical ionization source for mass spectrometry
ATE214419T1 (de) Heisshärtende wäschefeste rohbau-versiegelung
DE69732250D1 (de) Zyklische peptide mit breitspektrum antimikrobieller aktivität
DK0881906T3 (da) Farmaceutisk sammensætning til immunmodulation, som er baseret på peptider og adjuvanser
GB2308227B (en) Electrospray and atmospheric pressure chemical ionization mass spectrometer and ion source
DE69703449D1 (de) Neuroaktive peptide
WO2003074992A3 (en) Phosphorylated proteins and uses related thereto
NO995891D0 (no) LH-RH peptidanaloger, anvendelser og farmasöytiske blandinger inneholdende disse
Kidwell et al. Sequencing of peptides by secondary ion mass spectrometry
EP1983059A3 (de) Reaktionsgemische zur Herstellung von Dipeptiden
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
WO2004018644A3 (en) HETEROGENEOUS FOLDAMERS CONTAINING α, β, AND/OR Ϝ-AMINO ACIDS
GB9816514D0 (en) Novel method
AUPR378001A0 (en) Protein chip
WO1999020760A3 (en) Herg family potassium ion channel genes and protein
WO2002037121A3 (en) Detection of modified amino acids by mass spectrometry
AU2002322506A1 (en) Non-affinity based isotope tagged peptides and methods for using the same
AU2172597A (en) Protein phosphatase-1 catalytic subunit interactions
Yamaguchi et al. Enhancement of MALDI-MS spectra of C-terminal peptides by the modification of proteins via an active ester generated in situ from an oxazolone
Wang et al. Screening combinatorial libraries for optimal enzyme substrates by mass spectrometry
WO1999042578A3 (en) Modulation of cell proliferation, methods and reagents
WO2003087805A3 (en) Method for efficiently computing the mass of modified peptides for mass spectrometry data-based identification

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties